Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter

  title={Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter},
  author={Krista M. Dale and C. Michael White},
  journal={Annals of Pharmacotherapy},
  pages={599 - 605}
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of dronedarone for the treatment of atrial fibrillation. Data Sources: A literature search was conducted using the search terms dronedarone, SR 33589, atrial fibrillation, and antiarrhythmic medication in MEDLINE (1966–February 2007), International Pharmaceutical Abstracts (1970–February 2007), and EMBASE (1990–February 2007). References from the identified trials and selected review articles were… 

Tables from this paper

Dronedarone: A New Antiarrhythmic Agent for the Treatment of Atrial Fibrillation

Dronedarone is likely to be a useful addition to the therapeutic management of AF and further comparative studies with amiodarone are needed to define dron Cedarone's place in therapy more clearly.

Dronedarone: A New Antiarrhythmic Agent

Dronedarone represents a reasonable alternative for maintenance of sinus rhythm in appropriately selected patients and a possible increase in mortality in patients with New York Heart Association class IV or II‐III heart failure with a recent decompensation.

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.

Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?

  • J. Reiffel
  • Medicine, Biology
    Journal of atrial fibrillation
  • 2013
Dronedarone slows the ventricular response, can prolong the time to/reduce recurrences of/ reduce progression of AF, and reduce the incidence of hospitalization in AF patients with risk-prone markers, but trials have also revealed an increased risk of mortality and other adverse cardiovascular outcomes from dron Cedarone when given to patients in heart failure.

Dronedarone for atrial fibrillation therapy

Dronedarone is a new benzofuran derivative that has been developed as an antiarrhythmic agent on the basis of the amiodarone molecular structure with the intent of maintaining the same

Dronedarone: current evidence and future questions.

Dronedarone appears to have improved tolerability at the expense of decreased efficacy when compared to amiodarone, which is not appropriate in patients with recently decompensated heart failure or those treated with strong CYP3A4 inhibitors or medications prolonging the QT interval.

Role of New Drugs for Management of Atrial Fibrillation

Use of dronedarone should be limited to patients with paroxysmal or persistent AF and should not be used in patients with heart failure or with permanent AF, and apixaban appears to offer a pharmacoeconomic advantage over warfarin at no to minimal cost.

Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone

Recent trial data from a new antiarrhythmic agent, dronedarone, suggest that this drug may be a safe alternative to amiodarone; however, its long-term efficacy and safety still require exploration.

Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study.

Dronedarone appears to be a good therapeutic option in the treatment of atrial fibrillation in patients with amiodarone-induced hyperthyroidism, however, long-term studies are needed to estimate the efficacy and toxicity of both drugs.



Dronedarone: a new antiarrhythmic agent.

Dronedarone at the dose of 400 mg twice daily was effective in preventing both symptomatic and asymptomatic recurrences of atrial fibrillation or atrial flutter and had a safety profile similar to that of placebo.

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects

Addition of dronedarone to metoprolol increases bioavailability of metoprool in CYP2D6 extensive metabolizers and induces an additive dron Cedarone dose‐dependent negative inotropic effect, which was modest at 800 mg daily (anticipated therapeutic dose).

Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study

Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardioverting AF or AFl to SR and significantly effective in maintaining SR for 1 year.

Chronic and Acute Effects of Dronedarone on the Action Potential of Rabbit Atrial Muscle Preparations: Comparison With Amiodarone

Chronic and acute electrophysiologic effects of dronedarone on rabbit atrial muscle are similar to those of amiodarone, suggesting a similar potential against atrial arrhythmias.

SR 33589, a New Amiodarone‐like Antiarrhythmic Agent: Electrophysiological Effects in Anesthetized Dogs

It is suggested that acute administration of SR 33589 results in electro-physiological actions similar to those produced by amiodarone, and prolonged VERP more at longer CL than at shorter CL, but the degree of reduction at short CL was less with SR 335 89 than with amioarone.

Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship.

MDEa, DDEA, and B2-O-EtOH rank in order of decreasing toxicity toward alveolar macrophages, indicating that dealkylation and deamination of the diethylaminoethoxy group represent important mechanisms of detoxification.

Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome

The absence of TdP with amiodarone seems to be related to homogeneous APD lengthening in the majority of dogs and the lack of EADs and/or ventricular ectopic beats in all.